Company News
-
Jun 27, 2022Clover's COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster
-
Jun 13, 2022Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
-
Jun 5, 2022Clover Provides Update on 2022 Corporate Milestones
-
May 31, 2022Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
-
May 5, 2022Clover's Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
-
Apr 27, 2022Clover Appoints LiongHo Chua as President of Greater China
-
Apr 20, 2022Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease
-
Apr 19, 2022Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022
-
Mar 29, 2022Clover Reports Full Year 2021 Financial Results
-
Mar 17, 2022Clover's COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster
-
Feb 24, 2022Clover Selected for Inclusion on the Hang Seng Composite Index
-
Feb 14, 2022Clover Provides Corporate Update and 2022 Priorities
-
Feb 1, 2022Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
-
Jan 21, 2022Clover's Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet
-
Jan 5, 2022Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA
-
Jan 5, 2022Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai
-
Dec 9, 2021Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis
-
Dec 7, 2021Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF
-
Nov 26, 2021Clover's COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
-
Nov 18, 2021Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a Booster
